Therapeutic clearance of amyloid by antibodies to serum amyloid P component

New England Journal of Medicine

Volumn 373, Issue 12, 2015, Pages 1106-1114

  Richards, Duncan B ^a   Cookson, Louise M ^a   Berges, Alienor C ^a   Barton, Sharon V ^a   Lane, Thirusha ^b   Ritter, James M ^b   Fontana, Marianna ^b,c   Moon, James C ^b   Pinzani, Massimo ^b   Gillmore, Julian D ^b   Hawkins, Philip N ^b   Pepys, Mark B ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [6 (2 CARBOXY 1 PYRROLIDINYL) 6 OXOHEXANOYL] 2 PYRROLIDINECARBOXYLIC ACID; AMYLOID; BIOLOGICAL MARKER; HUMANIZED MONOCLONAL IMMUNOGLOBULIN SERUM AMYLOID P COMPONENT G1 ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; UNCLASSIFIED DRUG; CARBOXYLIC ACID; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PYRROLIDINE DERIVATIVE; R-1-(6-(R-2-CARBOXYPYRROLIDIN-1-YL)-6-OXOHEXANOYL)PYRROLIDINE-2-CARBOXYLIC ACID; SERUM AMYLOID P;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ELASTOGRAPHY; EXTRACELLULAR SPACE; FEMALE; HUMAN; INFUSION RELATED REACTION; LIVER FUNCTION; LYMPH NODE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADULT; AGED; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; CARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULIN G; INFUSIONS, INTRAVENOUS; LIVER; MIDDLE AGED; PYRROLIDINES; SERUM AMYLOID P-COMPONENT;

EID: 84942042128     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1504942     Document Type: Article

References (25)

1. Pepys MB . Amyloidosis. Annu Rev Med 2006; 57: 223-41.
2. Pepys MB, Hawkins PN. Amyloidosis. In: Warrell DA, Cox TM, Firth JD, eds. Oxford textbook of medicine. 5th ed. Oxford, United Kingdom: Oxford University Press, 2010: 1766-79.
3. Venner CP, Gillmore JD, Sachchithanantham S, et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-Adapted cyclophosphamide, thalidomide a nd dexamethasone (CTD) in AL amyloidosis. Leukemia 2014; 28: 2304-10.
4. Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417: 254-9.
5. Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010; 468: 93-7.
6. Pepys MB,Booth DR,Hutchinson WL,Gallimore JR,Collins PM,Hohenester E. Amyloid P component: a critical review. Amyloid Int J Exp Clin Invest 1997, 4, 274-95
7. Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol 1979; 38: 284-93.
8. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990; 323: 508-13.
9. Gillmore JD, Tennent GA, Hutchinson WL, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 2010; 148: 760-7.
10. Kolstoe SE, Ridha BH, Bellotti V, et al. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci U S A 2009; 106: 7619-23.
11. Hawkins PN, Wootton R, Pepys MB. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest 1990; 86: 1862-9.
12. . Nelson SR, Tennent GA, Sethi D, et al. Serum amyloid P component in chronic renal failure and dialysis. Clin Chim Acta 1991; 200: 191-9.
13. Hutt DF, Lane T, Gillmore JD, et al. Role of dual modality I123 serum amyloid P component SPECT-CT imaging in amyloidosis. Amyloid 2010; 17: Suppl 1: 57.
14. Bandula S, Banypersad SM, Sado D, et al. Measurement of tissue interstit ial volume in healthy patients and those with amyloidosis with equilibrium contrastenhanced MR imaging. Radiology 2013; 268: 858-64.
15. Banypersad SM, Sado DM, Flett AS, et al. Quantification o f myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2013; 6: 34-9.
16. Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013; 15: 92.
17. Lanzi A, Gianstefani A, Mirarchi MG, Pini P, Conti F, Bolondi L. Liver AL amyloidosis as a possible cause of high liver stiffness values. Eur J Gastroenterol Hepatol 2010; 22: 895-7.
18. Loustaud-Ratti VR, Cypierre A, Rousseau A, et al. Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid 2011; 18: 19-24.
19. Sahota T, Berges A, Barton S, Cookson L, Zamuner S, Richards D. Target mediated drug disposition model of CPHPC in patients with systemic amyloidosis. CPT Pharmacometrics Syst Pharmacol 2015; 4(2): e15.
20. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47: 380-4.
21. Dyck RF, Lockwood CM, Kershaw M, et al. Amyloid P-component is a constituent of normal human glomerular basement membrane. J Exp Med 1980; 152: 1162-74.
22. Breathnach SM, Melrose SM, Bhogal B, et al. Amyloid P component is located on elastic fibre microfibrils in normal human tissue. Nature 1981; 293: 652-4.
23. Lovat LB, Persey MR, Madhoo S, Pepys MB, Hawkins PN. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut 1998; 42: 727-34.
24. Pepys MB. Combinations of SAP depleting agents and anti-SAP antibodies. US Patent No. 7,910,106, issued March 22, 2011.
25. Simons JP, Al-Shawi R, Ellmerich S, et al. Pathogenetic mechanisms of amyloid A amyloidosis. Proc Natl Acad Sci U S A 2013; 110: 16115-20.